ABBV — AbbVie Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1551152 ·
Last close
$261.59
Market Cap
$462.26B
52W High
$269.39
52W Low
$189.40
ADV30
4,191,888
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 16,990,000,000 | 12,699,000,000 | 6,723,000,000 | 3,613,000,000 | 135,115,000,000 | 6,569,000,000 | 141,003,000,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 16,618,000,000 | 12,066,000,000 | 5,809,000,000 | 1,816,000,000 | 133,960,000,000 | 5,229,000,000 | 137,188,000,000 |
| Sep 2025 | 15,776,000,000 | 10,472,000,000 | 4,584,000,000 | 186,000,000 | 133,898,000,000 | 5,629,000,000 | 136,497,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,507,000,000
Investing CF
$-6,498,000,000
Financing CF
$-12,891,000,000
CapEx
$-1,297,000,000
Dividends Paid
$-11,978,000,000
Buybacks
$-1,505,000,000
EPS Diluted TTM
$3.54
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-17,333,000,000
Inventory
$5,127,000,000
Receivables
$13,824,000,000
ST Investments
$28,000,000
EBIT TTM
$11,615,000,000
Pretax Income TTM
$8,699,000,000
Interest Exp TTM
$2,916,000,000
Analysts
28
Yahoo Snapshot (yfinance, live)
Total Revenue
$64,385,998,848
EBITDA
$30,762,999,808
Free Cash Flow
$16,870,250,496
Enterprise Value
$518,724,190,208
Total Cash
$6,568,999,936
Total Debt
$70,884,999,168
Shares Out
1,767,117,285
Trailing EPS
$3.55
Book Value
$-3.36
ROE
—
ROA
10.5%
Div Yield
2.69%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 61,160,000,000 | 20,091,000,000 | 4,226,000,000 | 133,960,000,000 | 137,188,000,000 | -3,270,000,000 | 19,030,000,000 |
| Dec 2024 | 56,334,000,000 | 11,894,000,000 | 4,278,000,000 | 135,161,000,000 | 131,797,000,000 | 3,325,000,000 | 18,806,000,000 |
| Dec 2023 | 54,318,000,000 | 13,535,000,000 | 4,863,000,000 | 134,711,000,000 | 124,314,000,000 | 10,360,000,000 | 22,839,000,000 |
| Dec 2022 | 58,054,000,000 | 18,814,000,000 | 11,836,000,000 | 138,805,000,000 | 121,518,000,000 | 17,254,000,000 | 24,943,000,000 |
TTM Snapshot
Revenues TTM
$56,542,000,000
NetIncome TTM
$8,574,000,000
OpCashFlow TTM
$0
Assets (Latest)
$133,960,000,000
Forward EPS
$16.28
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $230.00 · spot: $261.59 · call volume: 329 · put volume: 1,050
Expected Move to 2027-02-19:
±$37.80
(14.45%) —
implied range
$223.79 –
$299.39
· ATM straddle on $260.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| JNJ | JOHNSON & JOHNSON | $638.00B | $264.74 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
| NVSEF | NOVARTIS AG | $267.87B | $140.93 | — |
| AZN | ASTRAZENECA PLC | $250.42B | $161.47 | — |
News headlines (Yahoo Finance, 1h cache)
AbbVie Stock: Buy, Sell, or Hold in October?
2026-09-30 16:50 · Yahoo
What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update?
2026-09-30 15:10 · Yahoo
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
2026-09-30 13:40 · Yahoo
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
2026-09-30 11:15 · Yahoo
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
2026-09-30 09:45 · Yahoo
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
2026-09-30 05:30 · Yahoo
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
2026-09-30 05:00 · Yahoo
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
2026-09-29 20:45 · Yahoo
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval
2026-09-29 16:19 · Yahoo
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
2026-09-29 15:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.